Compare Intuitive Machines (LUNR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Machines vs Organon & Co. Common Stock — how do they compare? Intuitive Machines trades at $10.79 (market cap $1.97B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Intuitive Machines pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Machines for 7 Days and Organon & Co. Common Stock for 0 Days on average.
| LUNR | OGN | |
|---|---|---|
Market Cap | $1.97B | $3.62B |
Volume | 6,024,737 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $45.70 | $13.81 |
52-Week Low | $8.05 | $5.70 |
Typical Hold Time | 7 Days | 0 Days |
Enterprise Value | $2.04B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Machines (LUNR) trades at $12.18, down 5.29% on the day, reflecting a bearish technical trend. The company is in a high-growth phase, with revenue projected to surge from $207 million in 2025 to $481 million in 2026, but it remains deeply unprofitable with a net loss margin of -27.1%. Recent news highlights its strategic position in lunar infrastructure and satellite manufacturing, supported by NASA contracts, though the stock faces pressure from broader sector weakness.
The investment case hinges on execution of its growth strategy amid significant cash burn. Analyst consensus is strongly bullish with an $31.33 price target, but high execution risk and persistent losses present a speculative opportunity. Key risks include dependence on government contracts and intense competition in the space sector.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Machines
Intuitive Machines provides lunar access, data, and infrastructure services. Its capabilities include lunar landers, communications systems, and technologies designed to support missions to the Moon.
Read more on LUNR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
